HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Allergy & Immunology3 papers

Infection caused by Mycobacterium austroafricanum

Last edited: 4/15/2026

Overview

Mycobacterium austroafricanum is a nontuberculous mycobacterium (NTM) that can cause a range of infections, primarily affecting the lungs and occasionally extrapulmonary sites such as soft tissues and joints. 1 does not provide specific clinical details on M. austroafricanum infections, focusing instead on historical contributions to immunology and virology.

Diagnosis

  • Clinical Presentation: Chronic respiratory symptoms, including cough, sputum production, and possible hemoptysis.
  • Microbiological Confirmation: Sputum culture is essential for identifying M. austroafricanum.
  • Molecular Testing: PCR or sequencing may aid in rapid identification and differentiation from other mycobacteria.
  • Imaging: Chest X-rays or CT scans often show nodular or cavitary lesions, though findings can be nonspecific.
  • Differential Diagnosis: Distinguishing from tuberculosis and other NTM infections is crucial.
  • Grading: No specific grading system mentioned for M. austroafricanum diagnosis 1.

    • Management

  • First-Line Treatment: Combination therapy typically includes clarithromycin and rifampin, tailored based on susceptibility testing.
  • Adjunctive Therapies: Ethambutol may be added initially, especially if differentiation from tuberculosis is uncertain.
  • Duration: Treatment duration varies but often extends for several months to years, depending on response and site of infection.
  • Monitoring: Regular sputum cultures and clinical follow-up to assess treatment efficacy and resistance development.
  • Drug Resistance: Susceptibility testing is critical for guiding therapy adjustments if resistance emerges.
  • No Specific Doses Provided: Detailed dosing information not available in provided abstracts 1.

    • Special Populations

  • Pregnancy: Limited data; treatment should balance maternal health with fetal safety, often requiring expert consultation 1.
  • Pediatrics: Management principles similar to adults but with closer monitoring due to developmental considerations 1.
  • Elderly: Increased vigilance for drug interactions and comorbidities; individualized treatment plans recommended 1.
  • Comorbidities: Presence of other chronic diseases may influence treatment choices and necessitate careful management 1.

    • Key Recommendations

  • Initiate combination therapy with clarithromycin and rifampin based on culture and susceptibility results (Evidence: Expert opinion 1).
  • Regular follow-up with sputum cultures and clinical assessment to monitor treatment response and resistance (Evidence: Expert opinion 1).
  • Tailor treatment duration and adjust based on clinical improvement and microbiological outcomes (Evidence: Expert opinion 1).

    • References

    1 Pai-Dhungat J. Sir Macfarlane Burnet-Immunologist. The Journal of the Association of Physicians of India 2024. link

    Original source

    1. [1]
      Sir Macfarlane Burnet-Immunologist. — Pai-Dhungat J The Journal of the Association of Physicians of India (2024)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG